Subcutaneous bortezomib in multiple myeloma patients induces similar therapeutic response rates as intravenous application but it does not reduce the incidence of peripheral neuropathy.

Subcutaneous bortezomib in multiple myeloma patients induces similar therapeutic response rates as intravenous application but it does not reduce the incidence of peripheral neuropathy.

OBJECTIVE:Subcutaneous (SC) application of bortezomib has been recently introduced as a new application route in multiple myeloma (MM) patients. We performed an analysis to compare the outcomes of bortezomib-based therapy in multiple myeloma (MM) patients treated using either intravenous (IV) or sub...

Full description

Bibliographic Details
Main Authors: Jiri Minarik, Petr Pavlicek, Ludek Pour, Tomas Pika, Vladimir Maisnar, Ivan Spicka, Jiri Jarkovsky, Marta Krejci, Jaroslav Bacovsky, Jakub Radocha, Jan Straub, Petr Kessler, Marek Wrobel, Lenka Walterova, Michal Sykora, Jarmila Obernauerova, Lucie Brozova, Evzen Gregora, Dagmar Adamova, Jaromir Gumulec, Zdenek Adam, Vlastimil Scudla, Roman Hajek, Czech Myeloma Group
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2015-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4396992?pdf=render

Internet

http://europepmc.org/articles/PMC4396992?pdf=render

Similar Items